Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
ALDERLEY PARK - TheraCryf plc (AIM:TCF), a clinical stage drug development company specializing in treatments for brain diseases, has announced its full-year results for the period ending March 31, 2025. The company reported a post-tax loss of £1.9 million, an improvement from the previous year’s loss of £3.1 million, and a cash balance of £4.1 million, up from £2.0 million the year before.
Key operational highlights include a successful capital raise of £5.15 million, with the majority (£4.25 million) secured in February 2025. This funding extends the company’s cash runway from Q4 2025 to Q4 2026, ensuring the orexin-1 antagonist (Ox-1) program for treating addiction is funded to clinical readiness. TheraCryf now ranks in the top 20% of European listed biotech companies by duration of cash runway.
The company welcomed Dr. Alastair Smith as the new Chair in February 2025. The period also saw the completion of the acquisition of Chronos Therapeutics Ltd in April 2024, leading to a strategic refocus on brain disorders and acceleration of the Ox-1 program. A European patent was granted in December 2024 for Ox-1, extending protection until 2038.
The company’s SFX-1 Phase 1 volunteer study was published in a peer-reviewed journal, and pre-clinical work on glioblastoma began in collaboration with Erasmus Medical (TASE:BLWV) Centre Rotterdam. TheraCryf is also in discussions to resolve a dispute with partner Stalicla SA.
Looking ahead, TheraCryf is concentrating its resources on developing the orexin-1 blocker addiction program to clinical readiness, with regulatory submission planned for 2026. The company has also partnered with leading CRO/CDMO Pharmaron UK Ltd for the pre-clinical development and manufacturing scale-up of Ox-1.
Dr. Huw Jones, CEO of TheraCryf, emphasized the company’s strong position following the acquisition of Chronos Therapeutics and the focus on cash management amid challenging markets. He expressed confidence in the potential of the orexin-1 antagonist to address addictive disorders and the company’s ability to deliver value inflection points.
An investor presentation on the results will be held via Investor Meet Company, open to both existing and potential shareholders.
This report is based on a press release statement from TheraCryf plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.